News
Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...
8h
HealthDay on MSNTirzepatide Dispensations Increased Rapidly After ApprovalAfter approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes prescribed ...
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...
When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in with the new.
The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and cardiovascular health has significant implications for orthopedic surgery.GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results